Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Ad, Social Media Claims Scrutinized; Unilever Slims Down; Perrigo Generic Advil Congestion Ready

This article was originally published in The Tan Sheet

Executive Summary

NAD refers RDK Global advertising to FTC; social media claims trigger FDA warning; Perrigo to launch equivalent of Advil product; Unilever divests Slim-Fast; class-action complaint against Nu Skin; Herbalife makes friends on Capitol Hill; and child-proof liquid nicotine bill introduced.

You may also be interested in...



Health, Beauty And Wellness Transaction News: SlimFast To Glanbia, More MedMen Moves, Empower Production Partner

Glanbia adds SlimFast to its lineup; MedMen making moves in cannabis market; and production partner for Empower medical cannabis.

Adding Zarbee's, J&J Gains Natural Market Footprint, Claims Credibility

Zarbee's Naturals vitamin, mineral and dietary supplement products were launched in 2008 by a physician interested in offering non-drug alternative remedies for children and adults for indications such as cough and cold, sore throat, immune support, sleep and digestive health. J&J on the other hand, has been challenged in class action litigation about natural claims it's used on some of its Aveeno and Neutgrogena skin care product labels.

Janssen US Net Drug Prices Declined 5.7% in 2020; J&J Pushes Rebate Reform

Janssen's net drug prices declined for the fourth year in a row in 2020, while list prices increased 3.8%, according to the company's drug pricing report.

Topics

Related Companies

UsernamePublicRestriction

Register

PS107024

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel